Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Oct 9;124(15):2345-53.
doi: 10.1182/blood-2014-01-552166. Epub 2014 May 14.

6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study

Affiliations
Clinical Trial

6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study

Smita Bhatia et al. Blood. .

Abstract

Durable remissions in children with acute lymphoblastic leukemia (ALL) require a 2-year maintenance phase that includes daily oral 6-mercaptopurine (6MP). Adherence to oral 6MP among Asian-American and African-American children with ALL is unknown. We enrolled 298 children with ALL (71 Asian Americans, 68 African Americans, and 159 non-Hispanic whites) receiving oral 6MP for the maintenance phase. Adherence was measured electronically for 39 803 person-days. Adherence declined from 95.0% (month 1) to 91.8% (month 5, P < .0001). Adherence rates were significantly (P < .0001) lower in Asian Americans (90.0% ± 4.9%) and African Americans (87.1% ± 4.4%), as compared with non-Hispanic whites (95.2% ± 1.3%). Race-specific sociodemographic characteristics helped explain poor adherence (African Americans: low maternal education [less than a college degree: 78.9%, vs at least college degree: 94.6%; P < .0001]; Asian Americans: low-income households [<$50 000: 84.5%, vs ≥$50 000: 96.7%; P = .04]; households without mothers as full-time caregivers [85.6%] vs households with mothers as full-time caregivers [97.2%; P = .05]). Adherence rate below 90% was associated with increased relapse risk (hazard ratio, 3.9; P = .01). Using an adherence rate <90% to define nonadherence, 20.5% of the participants were nonadherers. We identify race-specific determinants of adherence, and define a clinically relevant level of adherence needed to minimize relapse risk in a multiracial cohort of children with ALL. This trial was registered at www.clinicaltrials.gov as #NCT00268528.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Adherence rates. (A) Adherence rate for the entire cohort over the 5 months of observation. (B) Adherence rate over time according to race. Test for heterogeneity: P < .0001; Asian Americans vs non-Hispanic whites: P = .01; African Americans vs non-Hispanic whites: P < .0001; African Americans vs Asian Americans: P = .41. (C) Adherence rate over time according to annual household income (<$50 000 vs ≥$50 000). (D) Adherence rate over time according to household structure (single parent/single child; nuclear family; single parent/multiple children). Test for heterogeneity: P = .05; single parent/single child vs single parent/multiple children: P = .1; nuclear family vs single parent/single child: P = .04; nuclear family vs single parent/multiple children: P = .6. (E) Adherence rate over time according to presence/absence of mother as the full-time caregiver. (A-E) Presented on the plots are the 95% CIs of model estimates.
Figure 2
Figure 2
Multivariable regression models with adherence rates dichotomized at 75%, 80%, 85%, 90%, 95%. Adjusted for NCI risk group, 6MP dose-intensity, blast chromosomal abnormalities, race, and for time from initiation of maintenance to study entry.

Comment in

  • It takes a village.
    Winick N. Winick N. Blood. 2014 Oct 9;124(15):2316-7. doi: 10.1182/blood-2014-05-576900. Blood. 2014. PMID: 25301330

References

    1. Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer. 2008;112(2):416–432. - PubMed
    1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166–178. - PubMed
    1. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18–24. - PubMed
    1. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18(2):115–136. - PubMed
    1. Chen IM, Harvey RC, Mullighan CG, et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood. 2012;119(15):3512–3522. - PMC - PubMed

Publication types

MeSH terms

Associated data